undamentalytics Newsletter
Sign in

Glucotrack, Inc. (GCTK) stock

Add to watchlist

Add holding +

NASDAQ: GCTK Nasdaq Health Care Equipment

Glucotrack, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds11 adding, 4 cuttingOf 1 active managers that changed their stake, 1 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Glucotrack, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Short interest rising. Shares sold short rose 50% in a month to 6.1% of tradable shares.

Price chart

  • 1 day-18.4%
  • 1 week-76.6%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
May 14, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Agreement
  3. Agreement
  4. Agreement
  5. Agreement
  6. Announcement
  7. Leadership
  8. Agreement
  9. Agreement
  10. Agreement
  11. Announcement
  12. Announcement
  13. Shareholder vote

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Glucotrack, Inc. valuation models and calculator

No model value for Glucotrack, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Glucotrack, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.5%: the 10-year Treasury yield (4.9%) plus a beta of 1 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no twelve-month earnings or share count in the filings yet
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: no twelve-month earnings or share count in the filings yet
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: no twelve-month earnings or share count in the filings yet
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: no twelve-month earnings or share count in the filings yet
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Glucotrack, Inc. with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Glucotrack, Inc.: too few analysts cover it.

Positioning

Short interest
6.1%
of tradable shares
Days to cover
0.04
at average volume
Short interest, 1 month
+50%
to October 15, 2026
Held by institutions
5%
of shares
Held by insiders
3.3%
of shares
Employees
15
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Price behaviour

52-week range
Not enough history
From 52-week high
—
vs 50-day average
—
vs 200-day average
—
Volatility (1 year)
—
Beta vs S&P 500
—

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$187,054
Institutions reporting
18
Shares held vs prior quarter
▲ 267.7%
Positions opened / closed
9 / 3

Top buyers and sellers, Q2 2026: 11 institutions bought and 4 sold ; the biggest buyer was HRT Financial LP (+165K shares) and the biggest seller Geode Capital Management, LLC (−13K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
HRT Financial LP $65,000 205K 34.7% ▲ 405.6%
Jane Street Group, LLC $40,978 128K 21.9% New
Citadel Advisors LLC $25,370 80K 13.6% New
Ikarian Capital, LLC $14,621 46K 7.8% 0.0%
Geode Capital Management, LLC $10,911 34K 5.8% ▼ 27.2%
Virtu Financial LLC $6,000 19K 3.2% New
Granite Islands Private Wealth, LLC $5,008 16K 2.7% New
Boothbay Fund Management, LLC $4,314 14K 2.3% 0.0%
UBS Group AG $4,257 13K 2.3% ▲ 1800.7%
Citigroup Inc $4,106 13K 2.2% New
Susquehanna International Group, LLP $3,364 11K 1.8% New
Alerus Financial Na $1,276 4K 0.7% 0.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Glucotrack, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around August 13, 2026 estimated from the company's past filing pattern, not announced

  • May 14, 2026
  • March 30, 2026
  • November 13, 2025
  • August 14, 2025
  • May 14, 2025
  • March 31, 2025

Recent SEC filings

Data status

When each part of this page on Glucotrack, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Glucotrack, Inc. in brief

What does Glucotrack, Inc. do?
Glucotrack, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Glucotrack, Inc.'s stock ticker?
Glucotrack, Inc. trades under the ticker GCTK on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Glucotrack, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are HRT Financial LP, Jane Street Group, LLC and Citadel Advisors LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.